LipiGo (Fucus vesiculosus)

LipiGo is a standardized extract of Fucus vesiculosus containing 70-95% fucoidan and polyphloroglucinols marketed for weight management. Currently, no human clinical trials have documented efficacy for weight loss or metabolic benefits despite its compositional profile.

Origin & History

LipiGo is a branded ingredient derived from Fucus vesiculosus (bladderwrack), a brown seaweed found in the North Atlantic and Baltic Sea. It consists primarily of a high-purity fucoidan concentrate (70-95% content) extracted from the thallus via proprietary aqueous processes, yielding an off-white to brown powder.

Historical & Cultural Context

No historical or traditional medicine uses are specified in the search results for Fucus vesiculosus or LipiGo. The research dossier contains no information about traditional systems, indications, or historical duration of use.

Health Benefits

• No clinical benefits documented - search results provide no human clinical trials, RCTs, or meta-analyses for LipiGo or Fucus vesiculosus extracts
• Compositional analyses show high fucoidan content (70-95%) but no efficacy data
• Contains polyphloroglucinols (0.5-25%) but no clinical outcomes reported
• GRAS status established for food use but no therapeutic benefits proven
• Weight management category placement lacks supporting clinical evidence

How It Works

LipiGo's fucoidan content (70-95%) theoretically inhibits lipase enzymes and modulates fat absorption in the digestive tract. The polyphloroglucinol compounds (0.5-25%) may influence adipocyte differentiation through PPAR-γ pathway modulation. However, these mechanisms remain unvalidated in controlled human studies.

Scientific Research

Search results provide no human clinical trials, RCTs, or meta-analyses specifically on LipiGo or Fucus vesiculosus extracts for any indication. No PubMed PMIDs are available in the results for such studies.

Clinical Summary

No randomized controlled trials, meta-analyses, or human clinical studies have evaluated LipiGo's efficacy for weight management or metabolic outcomes. While compositional analyses confirm high fucoidan content, this biochemical profile has not translated to demonstrated clinical benefits. The absence of human efficacy data represents a significant evidence gap for this marketed weight management ingredient.

Nutritional Profile

{"macronutrients": {"carbohydrates": "Low", "protein": "Low", "fat": "Negligible"}, "micronutrients": {"iodine": "High, approximately 100-300 mcg/g", "iron": "Moderate, approximately 2-5 mg/100g", "calcium": "Moderate, approximately 50-150 mg/100g"}, "bioactive_compounds": {"fucoidan": "High, approximately 70-95% of extract", "polyphloroglucinols": "Low, approximately 0.5-25% of extract"}, "bioavailability_notes": "Iodine is highly bioavailable, but the bioavailability of fucoidan and polyphloroglucinols in humans is not well-documented."}

Preparation & Dosage

No clinically studied dosage ranges are reported for LipiGo, Fucus vesiculosus extracts, powders, or standardized forms. Studies referenced do not include human dosing data. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research

Safety & Interactions

Safety data for LipiGo specifically is limited due to lack of clinical trials. Fucus vesiculosus generally may interact with anticoagulant medications due to fucoidan's blood-thinning properties. High iodine content in seaweed extracts may affect thyroid function and contraindicate use in hyperthyroid conditions. Pregnancy and lactation safety has not been established for this specific extract.